Futura Medical Hits Milestone with First Profit, Prepares for US Eroxon Launch

September 10, 2024 09:42 AM BST | By Team Kalkine Media
 Futura Medical Hits Milestone with First Profit, Prepares for US Eroxon Launch
Image source: Shutterstock

Futura Medical PLC (LSE:FUM) CEO James Barder recently discussed the company's latest financial performance and future outlook with Proactive's Stephen Gunnion. Barder highlighted that Futura Medical has raised its guidance for both profit and revenue for the remainder of the year, following a significant increase in revenue. The company’s flagship product, Eroxon, a clinically proven treatment for erectile dysfunction, has now been launched in ten countries, with its latest market entry in Mexico.

Barder underscored the importance of Eroxon's upcoming launch in the U.S. market, where it will become the first over-the-counter (OTC) treatment for erectile dysfunction, distinguishing itself from competitors such as Viagra and Cialis, which still require prescriptions. This entry into the U.S. market represents a strategic milestone for the company.

The CEO also detailed Futura Medical’s strategy for sustainable growth and a robust product pipeline, with plans for future regional expansions. This strategy is supported by the company’s successful track record, including its achievement of generating its first profit. Revenue for the period increased by over 300%, reaching £7 million.

With a strong research and development team and ongoing expansion initiatives, Barder expressed confidence in Futura Medical's potential for continued growth. The company is focused on establishing a viable presence in the consumer healthcare sector, leveraging its innovative products and strategic market entries to drive future success.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next